Appili Therapeutics prices 30M units at $0.025 in private placement

Appili Therapeutics (APLIF) announced a non-brokered private placement of up to approximately 30,000,000 units of the Company at a price of $0.025 per Unit for aggregate gross proceeds of up to approximately C$750,000. Each Unit, priced at $0.025, will consist of one Class A common share of the Company and one-half of one Common Share purchase warrant of the Company. Subject to receipt of shareholder approval, each Warrant will entitle the holder to acquire one Common Share at a price of C$0.05 per Common Share for 36 months from the closing date of the Private Placement, Pursuant to the requirements of the Toronto Stock Exchange, the Warrants will not be exercisable until such time as the Company obtains requisite shareholder approval, such approval to be sought no later than the next Annual General Meeting of the Company’s shareholders. If the Warrants do not receive shareholder approval, the Warrants will not be exercisable. The Company intends to use the net proceeds from the Private Placement primarily for working capital purposes and to fund the development of certain product candidates of the Company. The Private Placement is subject to certain closing conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX. The Company anticipates closing the Private Placement in November, 2025.